Quote:
Originally Posted by mrsD
This looks very promising. Thanks for putting up the link Echoes!
Baclofen is not the issue here. It is the process by which the baclofen modifies that is useful, and being compared to. The mention of baclofen
is a "comparison"....Drug studies that do that are typically more accurate than those done against placebos.
There is no evidence at this time that the new product would have any of the same side effects as baclofen. It will be a different drug with its own characteristics. It might be more difficult or less depending on the human trials.
I just saw a new commerical on TV this lunchtime, watching CNN.
It was by the MDA association. (muscular dystrophy). It claimed
many new drugs coming for muscle and nerve treatment within the upcoming 5 years. Perhaps this is one of those?
|
What you say about Baclofen is probably true. We really do not know. And we do not know if there will be human trials or not. At any rate, this probably has a long way to go. It might be just the thing and we won't know until we hear further. Again, it is for CMT1A.
As far as the MDA association and new drugs for muscle and nerve treatment within the upcoming 5 years - again we do not know if it would be for CMT1A. I will be seeing this on their site and in their magazine I get. There are many types of Muscular Dystrophy and Charcot Marie Tooth disease is not one of them. CMT is of the peripheral nervous system (PNS) and Muscular Dystrophy is of the central nervous sytem (CNS). People who have MS are born with diseased muscles. CMTer's are born with healthy muscles. Again, CMT is not any type of MS. So time will tell.